

June 16, 2017

The logo features the word "DCAT" in blue, "TOP" in orange with an upward-pointing arrow, and "Industry NEWS" in blue.

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

More successful NDA approvals
than any other. Delivered.

The Patheon logo includes the tagline "A HEALTHIER WORLD. DELIVERED." and a background of blue and green bubbles.

1. US Supreme Court Makes Landmark Decision in Biosimilar Case

In a ruling that impacts commercial launches of biosimilars, the US Supreme Court has ruled in favor of biosimilar developers regarding notification requirements by a biosimilar developer to an innovator drug company in a case between Sandoz, the generic drug arm of Novartis, and Amgen. [Read More](#)

2. BMS To Sell Small-Molecule API Plant to SK Biotek

Bristol-Myers Squibb has agreed to sell its small-molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to SK Biotek, a wholly owned subsidiary of SK Holdings, based in Seoul, South Korea. SK Biotech plans to operate the plant as a stand-alone CDMO. [Read More](#)

3. Olon Acquires Ricerca Biosciences' Chemical Division

Olon S.p.A., an Italy-headquartered CDMO of active pharmaceutical ingredients, has acquired the Chemical Division of Concord, Ohio-based Ricerca Biosciences, a contract research organization and CDMO. [Read More](#)

4. Dr. Reddy's Recalls Acne Medicine Made at Cipla Plant

Dr. Reddy's Laboratories is voluntarily recalling 765,018 cartons of Zenatane (isotretinoin) capsules, an acne medicine, in three dose sizes, due to failed dissolution specifications. The products were manufactured by Cipla at its plant in Pune, India. [Read More](#)

5. Otsuka Subsidiary To Expand High-Potency Manufacturing

Taiho Pharmaceutical, part of the Japanese pharmaceutical company, Otsuka, broke ground for the construction of a new building for the production of highly potent active pharmaceutical ingredients at its site in Saitama, Japan. [Read More](#)

6. Japan's Sawai Completes \$1 Billion Buy of UpsherSmith's Generics Biz

Sawai Pharmaceutical, a Japanese generic pharmaceuticals manufacturer, has completed its previously announced acquisition of the generics business of UpsherSmith, a Minneapolis, Minnesota-based privately held company, for \$1.05 billion. [Read More](#)

7. FDA Requests Removal of Endo's Opioid Pain Drug

The FDA has requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxycodone hydrochloride), from the market based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. [Read More](#)

8. [FDA To Assess Opioid Drugs with Abuse-Deterrent Properties](#)

FDA Commissioner Scott Gottlieb issued a statement to further amplify on the agency's plan to address ways to combat abuse of opioid drugs, which includes an upcoming public meeting in July that will address further abuse-deterrent formulations of opioid drugs. [Read More](#)

9. [Boehringer Ingelheim Builds Lab for Digital Healthcare](#)

Boehringer Ingelheim has formed BI X as an independent subsidiary to focus on digital solutions in healthcare from idea to pilot. The start-up will work with all three business units of the company (human pharma, animal health, and biopharmaceuticals) to provide a platform for collaborating with specialists in data science, software development, and user-experience design. [Read More](#)

10. [Brexit Health Alliance Formed as New Stakeholder Group](#)

As the UK moves into negotiations with the European Union, a new alliance, the Brexit Health Alliance, has been formed as a multi-stakeholder interest group that brings together the UK's National Health Service and medical research, industry, patient, and public health organizations. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org